Compare ATMU & MMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATMU | MMSI |
|---|---|---|
| Founded | 1958 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.1B |
| IPO Year | 2023 | 1996 |
| Metric | ATMU | MMSI |
|---|---|---|
| Price | $52.08 | $71.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $58.25 | ★ $98.88 |
| AVG Volume (30 Days) | 704.4K | ★ 751.6K |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | ★ 12.61 | 4.93 |
| EPS | 0.59 | ★ 0.68 |
| Revenue | ★ $1,764,300,000.00 | $1,515,906,000.00 |
| Revenue This Year | $15.00 | $8.85 |
| Revenue Next Year | $5.13 | $5.88 |
| P/E Ratio | ★ $88.03 | $104.65 |
| Revenue Growth | 5.67 | ★ 11.75 |
| 52 Week Low | $37.12 | $59.74 |
| 52 Week High | $66.50 | $94.75 |
| Indicator | ATMU | MMSI |
|---|---|---|
| Relative Strength Index (RSI) | 53.92 | 56.70 |
| Support Level | $50.67 | $66.19 |
| Resistance Level | $54.55 | $71.96 |
| Average True Range (ATR) | 1.92 | 1.87 |
| MACD | 0.12 | 0.10 |
| Stochastic Oscillator | 58.11 | 50.34 |
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. The company designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. It designs, manufactures, and sells filters, coolants, and chemical products. The company offers products including air filtration, coolants and chemicals, crankcase ventilation, fuel filtration, fuel cells, lube filtration, and others.
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.